Abstract
Background Despite reporting very few mpox cases early in 2023, Mainland China observed a surge with over 500 cases during the summer. Amid ambiguous prevention strategies and stigma surrounding mpox, the epidemic escalated silently. This study aims to quantify the epidemic scale and assess the transmission dynamics by estimating the effective reproduction number (Re) during its early phase.
Methods Publicly available data sources were aggregated to retrieve daily mpox incidences in Mainland China. The Re value was estimated employing an exponential growth model. This estimate was compared with Re values from 16 other national outbreaks in 2022 selected based on a cumulative incidence exceeding 700 symptomatic cases by the end of that year. A meta-analytic approach was adopted to compute the pooled mean of Re for selected outbreaks.
Results The estimated mean Re for Mainland China was 1.76 (95% credible interval: 1.51-2.06), suggesting a case doubling time of approximately two weeks. Re estimates from selected outbreaks of 2022 ranged from 1.17 for Portugal to 2.88 for Columbia. The computed pooled mean stood at 1.66 (1.40-1.92), aligning closely with the Re for Mainland China.
Limitations The study does not distinguish between indigenous and imported infections, which might impact the Re estimates. Furthermore, the analysis is limited by reporting delays and underascertainment, especially during the early phase of the epidemic.
Conclusions The initial transmission of mpox in Mainland China appeared largely unchecked, posing potential risks to vulnerable communities. These findings underscore the need for immediate and effective control measures, including targeted vaccination campaigns, to mitigate further spread and impact.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the National Science and Technology Council, Taiwan (NSTC #111-2314-B-002-289).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
